Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib
Soft tissue sarcomas encompass a wide range of histologic subtypes with varied clinical implications. The incorporation of comprehensive genetic profiling into clinical practice is refining our ability to make these distinctions in diagnosis to better reflect prognosis and clinical behavior of a tum...
Main Authors: | Erica V. Carballo, Tra V. Pham, Gulisa Turashvili, Krisztina Hanley, Kristen D. Starbuck, Jane L. Meisel |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-10-01
|
Series: | Gynecologic Oncology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578922001424 |
Similar Items
-
Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion
by: Ting Zhao, et al.
Published: (2023-03-01) -
Inflammatory myofibroblastic tumor of the submandibular gland Harboring MSN-ALK gene fusion: A case report and literature review
by: Limei Diao, et al.
Published: (2023-12-01) -
TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
by: Andrew Xiao, et al.
Published: (2023-05-01) -
Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
by: Lucheng Zhu, et al.
Published: (2022-11-01) -
Placenta-associated uterine inflammatory myofibroblastic tumor with a novel FBLN1-ALK1 fusion
by: Jaclyn C. Watkins, et al.
Published: (2022-06-01)